GLP-1 medications are associated with a modest increase in gallbladder events, likely due to rapid weight loss rather than direct effects on the gallbladder
Are there any contraindications for using Mounjaro (Tirzepatide) or Semaglutide
In addition to targeting GLP-1 and GIP like tirzepatide, retatrutide also targets glucagon receptors, which may account for its higher average weight loss figures of up to 28.7% in the phase 3 TRIUMPH-4 trial
Notably, despite constant progress in diverse aspects of natural drug monomers that protect against myocardial injury by activating the GSH system, great challenges remain in translating these compounds into future clinical pharmaceuticals
You know, I take that very seriously
Maybe AI-driven drug discovery accelerates this further, leading to treatments that fundamentally solve metabolic dysfunction